The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
Key Disease Targets in the STI Diagnostics Market While assay type and testing modality shape much of the market, segmenting STI and STD diagnostics by disease state provides clearer insight into where testing volume is concentrated and which infec- tions are driving the strongest growth. The market is defined by several major pathogen targets, each with distinct prevalence patterns, technology preferences and revenue contributions.
• HPV —one of the fastest-growing segments, increasing from USD 2.44 billion in 2025 to USD 3.94 billion by 2030 (10% CAGR), supported by more than 260 commercial tests globally— nearly half manufactured in Asia. 17 • Syphilis —a substantial and steadily expanding market valued at USD 2.29 billion in 2024 and expected to reach USD 4.57 billion by 2034 (6.85% CAGR), dominated by treponemal ELISA and CLIA assays. 19 • HIV —a major contributor valued at USD 1.1 billion in 2024 and projected to reach USD 1.55 billion by 2030 (5% CAGR), with rapid tests driving near-term adoption. 20 • Trichomoniasis —an increasingly recognized but historically under-prioritized STI, with the global trichomoniasis market projected to grow from USD 54.9 million in 2024 to USD 88.3 million by 2030 (8.4% CAGR). 21
Key segments include:
• Chlamydia/Gonorrhea (CT/NG) —the largest segment, driven by high prevalence, routine screening and broad product availability; CT/NG assays remain the highest-volume and among the fastest-growing categories, especially in molecular PCR workflows. 16 • HSV —a smaller but stable segment, estimated at USD 612 million in 2024 and growing at 5.96% CAGR. 18
Brochure
Improve Your Assay Stability: End-to-End Tailored Solutions for qPCR, Isothermal and NGS Enhance assay stability and performance with customized solutions for qPCR, isothermal amplification and NGS. Download the brochure to see how our end-to-end support can streamline your workflow.
18 | GENengnews.com
Powered by FlippingBook